DRKS00003261已完成4 期
Efficacy and safety of Neurodoron in patients with nervous exhaustion – a randomized, double-blind, placebo-controlled clinical trial –
WELEDA AGBereich Medizin/Medical Affairs0 个研究点目标入组 204 人开始时间: 2011年9月15日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one(—)
- 性别
- All
入选标准
- •1. Informed consent
- •2. At least 18 years of age
- •3. Confirmed diagnosis of nervous exhaustion according to the definition for neurasthenia as laid down in the WHO-criteria for research, characterized by either A.1 or A.2:
- •A.1 Persistent and distressing complaints of feelings of exhaustion after minor mental effort (such as performing or attempting to perform every-day tasks that do not require unusual mental effort),
- •A.2 Persistent and distressing complaints of feelings of fatigue and bodily weakness after minor physical effort
- •and B. at least one of the following symptoms:
- •feelings of muscular aches and pains, dizziness, tension headaches, sleep disturbance, inability to relax, irritability.
- •C. Inability to recover from A.1 or A.2 by normal periods of rest, relaxation or entertainment.
- •D. The duration of the disorder is at least 3 months.
排除标准
- •1. Concurrent or previous participation in clinical trials with trial drugs or other treatments for nervous exhaustion
- •2. Known hypersensitivity against wheat starch
- •3. Organic disease responsible for exhaustion (e.g. known heart, kidney or liver disease, uncontrolled diabetes mellitus, infection, iron deficiency anaemia, hypothyreotic metabolic situation)
- •4. Neuro-psychiatric disease causing exhaustion (e.g. psychosis, schizophrenia, dementia)
- •5. Organic brain syndrome (e.g. postencephalitic syndrome, sequelae of traumatic brain injury)
- •6. Presumed major depression, defined by BDI-II (Beck Depression Inventory) =29
- •7. Presumed major panic disorder or generalised anxiety disorder defined by GAD-7-score =16
- •8. Concomitant medication interfering with IMP, e.g. other drugs for treatment of stress/exhaustion/burnout, antidepressants or benzodiazepines during the last 4 weeks, initiation of treatment with oral beta-adrenoreceptorblockers
- •9. Known alcohol or drug abuse or dependency
- •10. Placement in an institution due to official directive or judicial order
- •11. Pregnancy, lactation
研究者
相似试验
进行中(未招募)
不适用
Effect of Neurodoron in patients with nervous exhaustionervous exhaustion (neurasthenia)MedDRA version: 14.0Level: LLTClassification code 10029200Term: Nervous exhaustionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-024189-23-DEWeleda AG
已完成
不适用
Efficacy and safety of minodronate in the treatment of glucocorticoid-induced osteoporosisJPRN-UMIN000011896Department of Medicine, School of Medicine, Nihon University30
尚未招募
1 期
euroEPO-Stroke. Phase I-IIStrokeRPCEC00000185Center of Molecular Immunology, CIMAB
进行中(未招募)
1 期
Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection.Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2EUCTR2020-001307-16-ESFundación para la Investigación Biomédica Hospital Ramón y Cajal104
已完成
早期 1 期
Midodrine and refractory gastroesophageal diseaseIRCT201402274226N2Shiraz University of Medical Sciences60
